Skip to content

Eulàlia Olesti

Department of Clinical Pharmacology, Area Medicament, Hospital Clinic of Barcelona, 08036 Barcelona, Spain; Clinical Pharmacology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.

2 papers in the library · 32 citations · publishing 2020-2023

Papers

Acute Effects of 2C-E in Humans: An Observational Study

Frontiers in Pharmacology March 18, 2020 Esther Papaseit, Marta Torrens, Mireia Ventura et al. 20 citations

2C-E, a psychedelic phenylethylamine similar to mescaline, acts as a partial agonist at serotonin 2A, 2B, and 2C receptors and inhibits norepinephrine and serotonin uptake. In an observational study, ten recreational psychedelic users self-administered single oral doses of 2C-E (6.5–25 mg). The drug induced alterations in perception, hallucinations, and euphoric mood, with saliva concentrations peaking 2 hours after administration. The effects resembled those of 2C-B and other serotonin-acting drugs.

Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie December 31, 2023 Francisco Madrid-Gambin, David Fabregat-Safont, Alex Gomez-Gomez et al. 12 citations

Psychedelics like LSD, mescaline, DMT, ayahuasca, 5-methoxy-DMT, and psilocybin induce altered states of consciousness and are being studied for treating mental health disorders. This review examines metabolic and metabolomics studies in humans after administration of these drugs. The main metabolites for classical psychedelics have been robustly established, but the metabolic alterations they induce need further exploration. Integrating metabolomics with pharmacokinetics may help understand the therapeutic role of psychedelics by revealing molecular interactions with multiple targets.